newsfilter
← Earnings
Earnings Releases·

Olema Oncology — Third Quarter 2026 Earnings Summary

  • Net loss widened to $73.6 million for Q3 2026 from $42.2 million in the prior year period, driven by a 69% increase in total operating expenses to $77.5 million, primarily due to higher R&D spending and stock-based compensation.
  • Cash and equivalents decreased by $91.6 million to $413.8 million as of September 30, 2026, reflecting increased spending on Phase 3 trial enrollment and clinical supply activities.
  • The company remains on track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in Q1 2027, with enrollment accelerating in the OPERA-02 trial and a new Phase 1b/2 combination study with Bayer expected to initiate in Q4 2026.
  • Management appointed Jason O'Byrne as Chief Financial Officer to support capital markets strategy and the company's transformation into a fully integrated oncology business ahead of 2027 catalysts.
Company
OLEMA PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology